Herceptin Sensitizes ErbB2–Overexpressing Cells to Apoptosis by Reducing Antiapoptotic Mcl-1 Expression

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Cancer Research

• Publication date

  2006-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-05-0754PMID 16467098
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.

  2005cited by this paper
• Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells

  2005cited by this paper
• Inhibition of Neutrophil Apoptosis by TLR Agonists in Whole Blood: Involvement of the Phosphoinositide 3-Kinase/Akt and NF-κB Signaling Pathways, Leading to Increased Levels of Mcl-1, A1, and Phosphorylated Bad

  2005cited by this paper
• BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly.

  2005cited by this paper
• Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells

  2005cited by this paper
• Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis.

  2005cited by this paper
• Specific Cleavage of Mcl-1 by Caspase-3 in Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis in Jurkat Leukemia T Cells*

  2005cited by this paper
• Bcl-2 antisense therapy in B-cell malignancies.

  2005cited by this paper
• Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin‐embedded breast cancer

  2005cited by this paper
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• Molecular dynamics study of peptide segments of the BH3 domain of the proapoptotic proteins Bak, Bax, Bid and Hrk bound to the Bcl-xL and Bcl-2 proteins

  2004cited by this paper
• Expression and prognostic relevance of Mcl-1 in breast cancer.

  2004cited by this paper
• NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis.

  2004cited by this paper
• Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing by a Novel Small Molecule Inhibitor of Bcl-2

  2004cited by this paper
• The Pathophysiology of Mitochondrial Cell Death

  2004cited by this paper
• Degradation of Mcl-1 by Granzyme B

  2004cited by this paper
• 1 VEGF INDUCES MCL-1 UPREGULATION AND PROTECTS MULTIPLE MYELOMA CELLS AGAINST APOPTOSIS

  2004cited by this paper
• Mcl-1 Is a Novel Therapeutic Target for Human Sarcoma

  2004cited by this paper
• The ErbB/HER receptor protein-tyrosine kinases and cancer.

  2004influential reference
• Mcl‐1 and Bcl‐2/Bax ratio are associated with treatment response but not with Rai stage in B‐cell chronic lymphocytic leukemia

  2004cited by this paper
• Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage

  2004cited by this paper
• The Bcl-2 protein family and its role in the development of neoplastic disease.

  2004cited by this paper
• Enhancement of the p27Kip1‐mediated antiproliferative effect of trastuzumab (Herceptin) on HER2‐overexpressing tumor cells

  2004cited by this paper
• Role of Myeloid Cell Factor-1 (Mcl-1) in Chronic Lymphocytic Leukemia

  2004cited by this paper
• New targeted therapies in breast cancer.

  2004cited by this paper
• S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast

  2004cited by this paper
• Downregulation of the antiapoptotic MCL‐1 protein and apoptosis in MA‐11 breast cancer cells induced by an anti‐epidermal growth factor receptor–Pseudomonas exotoxin a immunotoxin

  2004cited by this paper
• NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis

  2004cited by this paper
• Sensitization of chemotherapy by anti-HER

  2004cited by this paper
• Role of HER2/neu in tumor progression and therapy.

  2004influential reference
• The ErbB/HER receptor protein-tyrosine kinases and cancer*1

  2004cited by this paper
• Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.

  2004cited by this paper
• Therapeutic potential of antisense Bcl‐2 as a chemosensitizer for cancer therapy

  2004cited by this paper
• Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications.

  2004cited by this paper
• Trastuzumab for the Treatment of Non—Small-Cell Lung Cancer

  2003cited by this paper
• Dlx1, Dlx2, Pax6, Brn3b, and Chx10 homeobox gene expression defines the retinal ganglion and inner nuclear layers of the developing and adult mouse retina

  2003cited by this paper
• Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1

  2003cited by this paper
• Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.

  2003cited by this paper
• Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists.

  2003cited by this paper
• Increased expression of Mcl‐1 is responsible for the blockage of TRAIL‐induced apoptosis mediated by EGF/ErbB1 signaling pathway

  2003cited by this paper
• Role of HER2 in wound-induced breast carcinoma proliferation.

  2003influential reference
• Increased MCL–1 Expression Is Associated with Poor Prognosis in Ovarian Carcinomas

  2002cited by this paper
• Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

  2002cited by this paper
• Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.

  2001cited by this paper
• Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway

  2000cited by this paper
• Trastuzumab and chemotherapeutics: drug interactions and synergies.

  2000cited by this paper
• Mcl-1 deficiency results in peri-implantation embryonic lethality.

  2000cited by this paper
• Epidermal growth factor increases the level of the cyclin-dependent kinase (CDK) inhibitor p21/CIP1 (CDK-interacting protein 1) in A431 cells by increasing the half-lives of the p21/CIP1 transcript and the p21/CIP1 protein.

  1999cited by this paper
• Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse.

  1998cited by this paper
• ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner

  1998cited by this paper
• MCL‐1, a member of the BCL‐2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation

  1996cited by this paper
• Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells.

  1994cited by this paper

• Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer

  2025cites this paper
• Unlocking the power of probiotics, postbiotics: targeting apoptosis for the treatment and prevention of digestive diseases

  2025cites this paper
• Characterization of BCL-XL, MCL-1, and BAX Protein Expression in Response to Neoadjuvant Chemotherapy in Breast Cancer

  2024cites this paper
• Trastuzumab Induces Apoptosis and Cell Cycle Arrest in Triple-Negative Breast Cancer, Suggesting Repurposing Potential

  2024cites this paper
• Targeting MCL-1 protein to treat cancer: opportunities and challenges

  2023cites this paper
• Resistance to Trastuzumab

  2022cites this paper
• miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy

  2022cites this paper
• Preliminary evaluation and in vitro cytotoxicity studies of [131I]I-trastuzumab in HER2 expressing ovarian cancer cells

  2022cites this paper
• HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models

  2021cites this paper
• Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy

  2021cites this paper
• Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer

  2021cites this paper
• A Tetravalent Biparatopic Antibody Causes Strong HER2 Internalization and Inhibits Cellular Proliferation

  2021cites this paper
• Understanding MCL1: from cellular function and regulation to pharmacological inhibition

  2021cites this paper
• Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells

  2021cites this paper
• Allele-specific role of ERBB2 in the oncogenic function of EGFR L861Q in EGFR-mutant lung cancers.

  2020cites this paper
• Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis

  2020cites this paper
• Targeting apoptosis in cancer therapy

  2020cites this paper
• Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy.

  2019cites this paper
• MicroRNAs in cancer cell death pathways: Apoptosis and necroptosis.

  2019cites this paper
• Pre-clinical assessment of the co-operative effects of Trastuzumab and Panobinostat in HER2 overexpressing breast cancer

  2018cites this paper
• Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers

  2017cites this paper
• Function of myeloid cell leukaemia-1 and its regulative relations with hepatocellular carcinoma

  2017cites this paper
• Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin

  2017cites this paper
• Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

  2017cites this paper
• Gr upSM Current Advances in Breast Cancer Therapeutics : Implication of Gamma Delta T Cells

  2017cites this paper
• Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications

  2016cites this paper
• Bcl-2 family member Mcl-1 expression is reduced under hypoxia by the E3 ligase FBW7 contributing to BNIP3 induced cell death in glioma cells

  2015cites this paper
• Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer

  2015cites this paper
• Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration

  2015cites this paper
• Adjuvant Biologic Agents for Breast Cancer

  2015cites this paper
• Estrogen Regulation of Anti-Apoptotic Bcl-2 Family Member Mcl-1 Expression in Breast Cancer Cells

  2014cites this paper
• Rapid and sensitive phenotypic marker detection on breast cancer cells using surface-enhanced Raman scattering (SERS) imaging.

  2014cites this paper
• ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells

  2014cites this paper
• Apoptosis-related BCL2-family members: Key players in chemotherapy.

  2014cites this paper
• A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells

  2014cites this paper
• The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells

  2014cites this paper
• Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies

  2013cites this paper
• HER2 Phosphorylates and Destabilizes Pro-Apoptotic PUMA, Leading to Antagonized Apoptosis in Cancer Cells

  2013cites this paper
• Regulation of Apoptosis by HER2 in Breast Cancer.

  2013cites this paper
• Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

  2013cites this paper
• Predictive Biomarkers and Personalized Medicine Impact of c-MYC Protein Expression on Outcome of Patients withEarly-StageHER 2 þ BreastCancerTreatedwithAdjuvant Trastuzumab NCCTG ( Alliance ) N 9831

  2013cites this paper
• MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition

  2012cites this paper
• Mechanisms of resistance to lapatinib in HER2 positive breast cancer

  2012cites this paper
• HER2-Positive Breast Cancer

  2012cites this paper
• Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer

  2012cites this paper
• Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells.

  2012cites this paper
• Molecularly Targeted Therapeutics for Breast Cancer

  2012cites this paper
• Molecular analysis of the domain with no name (DWNN)/RBBP6 in human cancers

  2012cites this paper
• What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?

  2012cites this paper
• Les cancers du sein HER2 : que devons-nous retenir dans notre pratique clinique quotidienne ?

  2011cites this paper
• HER receptor-mediated dynamic signalling in breast cancer cells

  2011cites this paper
• Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation.

  2011cites this paper
• Role of Y-box binding protein-1 (YB-1) in breast cancer

  2011cites this paper
• C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

  2011cites this paper
• HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

  2011cites this paper
• Herceptin Conjugates Linked by EDC Boost Direct Tumor Cell Death via Programmed Tumor Cell Necrosis

  2011cites this paper
• Optimising the Development of Antibodies as Treatment for Cancer

  2011cites this paper
• [Her2 positive breast cancer: practices].

  2011cites this paper
• Truncated forms of BNIP3 act as dominant negatives inhibiting hypoxia-induced cell death.

  2011cites this paper
• Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer

  2011cites this paper
• c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1

  2011cites this paper
• The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications

  2011cites this paper
• Mcl‐1; the molecular regulation of protein function

  2010cites this paper
• ERBB2 Induces an Antiapoptotic Expression Pattern of Bcl-2 Family Members in Node-Negative Breast Cancer

  2010influential citation
• Inhibition of ErbB2 by Herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line

  2010cites this paper
• Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

  2010cites this paper
• Chemotherapy for breast cancer (Review).

  2010cites this paper
• Degradation of HER2 Receptor Through Hypericin‐mediated Photodynamic Therapy

  2010cites this paper
• ERBB 2 Induces an Antiapoptotic Expression Pattern of Bcl-2 Family Members in Node-Negative Breast Cancer

  2010influential citation
• Y-BOX BINDING PROTEIN-1 IS ESSENTIAL FOR THE GROWTH AND SURVIVAL OF HER2 OVER-EXPRESSING BREAST CANCERS AND MEDIATES TRASTUZUMAB RESISTANCE BY INDUCING CD44

  2010cites this paper
• Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity

  2010cites this paper
• Herceptin and breast cancer: an overview for surgeons.

  2010cites this paper
• HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

  2010cites this paper
• HER-2 signaling and inhibition in breast cancer.

  2009cites this paper
• Paradoxical concentration effect of a homodimerizing antibody against a human non-small cell lung cancer cell line

  2009cites this paper
• Unraveling the intricacies of spatial organization of the ErbB receptors and downstream signaling pathways

  2009cites this paper
• Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma

  2009cites this paper
• Multidisciplinary care for patients with breast cancer.

  2009cites this paper
• Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

  2009cites this paper
• Proliferation of breast cancer cells: regulation, mediators, targets for therapy.

  2008cites this paper
• The influence of diesel exhaust on polycyclic aromatic hydrocarbon-induced DNA damage, gene expression, and tumor initiation in Sencar mice in vivo.

  2008influential citation
• Caspase Cleavage of HER-2 Releases a Bad-like Cell Death Effector*

  2008cites this paper
• ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium.

  2008cites this paper
• Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer.

  2007cites this paper
• Diesel exhaust influences carcinogenic PAH-induced genotoxicity and gene expression in human breast epithelial cells in culture.

  2007cites this paper
• Cardiac dysfunction associated with trastuzumab

  2006cites this paper
• Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy.

  2006cites this paper
• The cardiotoxicity of chemotherapy: New prospects for an old problem

  2006cites this paper
• Capecitabine–docetaxel combination treatment

  2006cites this paper
• - 11-1-0600 TITLE : Probing HER 2-PUMA and EGFR-PUMA Crosstalks in Aggressive Breast Cancer

  year unknowncites this paper